Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
On Wednesday, JPMorgan analyst Eric Joseph adjusted the price target for PTC (NASDAQ:PTC) Therapeutics (NASDAQ:PTCT) to $67.00, decreasing from the previous target of $75.00. The firm sustained an Overweight rating on the stock. Joseph’s statement highlighted the company’s first quarter of 2025 earnings, which reported earnings per share (EPS) of $11.09, largely attributed to revenue recognized from a collaboration with Novartis (SIX:NOVN) (NVS). According to InvestingPro data, analyst targets for PTCT currently range from $40 to $113, with two analysts recently revising their earnings estimates upward for the upcoming period.
The analyst’s focus was drawn to the recent update on PTC Therapeutics’ PIVOT-HD data, which was presented yesterday, as well as forward-looking anticipation of the Prescription Drug User Fee Act (PDUFA) dates for Sephience in phenylketonuria (PKU) on July 29, and vatiquinone in Friedreich’s ataxia (FA) on August 19. Despite the recent pullback in PTC Therapeutics’ shares, which saw a 28% drop compared to a 7% decrease in the NASDAQ Biotechnology Index (NBI), Joseph suggested that the current share price may present a favorable opportunity for investors to engage with or increase their position in the company ahead of a summer with significant regulatory events. InvestingPro data shows the stock has fallen 27.39% in the past week, with technical indicators suggesting oversold conditions. The company maintains strong liquidity with a current ratio of 2.35, indicating solid short-term financial health.
The analyst expressed a more cautious outlook on the potential for accelerated approval following the PIVOT-HD update, considering it now "marginally less likely." However, the maintained Overweight rating indicates a continued positive stance on the stock’s prospects.
PTC Therapeutics is approaching a critical period with the upcoming PDUFA dates, which are key milestones for the company’s pipeline products Sephience and vatiquinone. The outcome of these regulatory reviews will be closely watched by investors and could have a notable impact on the company’s stock performance.
In other recent news, PTC Therapeutics reported strong financial results for the first quarter of 2025, with revenue reaching $190 million, surpassing the forecast of $167.54 million. This positive performance was largely driven by better-than-expected sales of Emflaza, which contributed $48 million, exceeding projections by $8 million. The company is also focusing on upcoming regulatory decisions for its products Sephience and vatiquinone, which are expected to support future growth. Citi analyst Geoff Meacham upgraded PTC Therapeutics’ stock from Sell to Neutral, noting the realignment of market expectations and potential opportunities ahead. Despite the revenue beat, the company faced a mixed market reaction, reflecting investor concerns over ongoing losses and future guidance. PTC Therapeutics maintains a strong cash position of over $2 billion, which supports its strategic initiatives and potential product launches. The company has provided full-year revenue guidance of $650-$800 million, indicating confidence in its product pipeline and market strategies. Upcoming regulatory decisions and product launches are anticipated to further bolster the company’s financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.